Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

HCV Progress in Therapy with Novel Sialomimetic-chimeric inhibitors

Objective

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV), which affects liver and is mainly transmitted by blood-to-blood contact. Infection is often asymptomatic, but when chronicized it causes liver inflammation (chronic hepatitis). This condition can progress to fibrosis, cirrhosis and cancer. Socio-economical quality of life is seriously affected by several aspects including domestic environment and workplace. Besides any ethical issue, the impact on the European and national health systems has a major relevance due to high costs of pharmacological treatments.
At present, no vaccine against HCV is available. Standard therapy is currently based on double or triple combination (peginterferon, ribavirin and protease inhibitor), but it is ineffective to reduce symptoms in about 40% of cases, while clearance from viremia is not achievable.
The market for HCV drugs is set to rapidly grow in the forthcoming years as new and more effective therapies will be available. Despite many scientific publications have envisaged during the most recent years the design and the study of new compounds targeting the glycans of the glycoproteins of the HCV envelope (gp120), no such kind of compounds have been described until now.
Recent patent publications (WO2008/090151and WO2011/064303) have described innovative HCV inhibitors targeting such glycoproteins of HCV envelope. Some of those compounds have been already tested in typical in vitro assays eliciting a remarkable inhibitory activity on HCV. It remains to assess their effectiveness by implementing additional work packages. The current comprehensive proposal has been designed to develop the scientific and technological bases to assess most of the findings required to enter into clinical studies in humans with new HCV inhibiting compounds.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-SME-2012
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

BSG-SME - Research for SMEs

Coordinator

UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
EU contribution
€ 72 500,00
Address
DUOMO 6
13100 Vercelli
Italy

See on map

Region
Nord-Ovest Piemonte Vercelli
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (7)

My booklet 0 0